[email protected]

+44 (0)20 3773 4895

logologologo
  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • Academic Courses
      • Digital Health Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Digital Health
      • Obesity Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Obesity Care
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Subscribe
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login

No products in the cart.

logologologo
  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • Academic Courses
      • Digital Health Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Digital Health
      • Obesity Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Obesity Care
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Subscribe
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login

No products in the cart.

  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • Academic Courses
      • Digital Health Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Digital Health
      • Obesity Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Obesity Care
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Subscribe
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login
April 19, 2018 by Nigel Hinchliffe GLP-1s & Medications 0 comments

How Physiological Changes Associated with Obesity Affect Drug Metabolism

Obesity is known to have a significant impact on many organ systems that are crucial in drug metabolism. As the prevalence of obesity continues to rise, clinicians are being challenged with the problem of dosing in the extreme overweight population. This review article discusses the different physiological changes associated with obesity and how they affect absorption, distribution, drug metabolism and clearance in morbidly obese patients.

The changes that occur in the organs of the body do not correlate linearly with BMI, but also includes factors such as time and individual body composition. For example, in the kidney of an obese patient, renal clearance is initially enhanced by a compensatory hyperfiltration and hyper-perfusion, though, eventually, this declines as a result of a constantly elevated intra-glomerular pressure which leads to chronic kidney disease. Likewise, cardiac output is increased in obese patients in order to provide oxygen and nutrients to the excess tissue. This should mean that that blood flow to the liver increases, however due to non-alcoholic fatty liver disease resulting in steatosis, together with sinusoidal narrowing, blood flow may actually decrease over time.

Obesity also has an effect on the gastric emptying and gut permeability, meaning that drugs are absorbed at different rates to normal. Drug penetration into tissue is also affected, meaning that a higher dose may be needed in order to reach effective concentrations. For example, with antibiotics to treat a local infection, obese patients may require a much higher dose, which can then introduce issues of drug toxicity.

What is clear from these few examples is that with a growing number of obese patients, there needs to be a quantitative system in place that can derive drug dosing recommendations for obese patients. Currently there is a lack of understanding of how obesity affects the pharmacokinetics and pharmacodynamics of drugs, which leads to improper and potentially dangerous dosing of obese patients.

To learn more about obesity, its prevention, and its treatment please look at CCH’s Postgraduate Academic Courses in Obesity Care, and CPD Short Courses in topics such as childhood obesity and behaviour change, designed to up-skill health professionals in this vitally important, and often overlooked, area of care.

PREV
NEXT

Related Posts

Three obesity medication pens on a desk.
March 20, 2025
Early use of anti-obesity medication more than doubles weight loss
Read More
Manchester Town Hall in England.
December 12, 2025
Manchester Launches Landmark Five-Year Mounjaro Trial to Assess Real-World Outcomes
Read More
A man holding a paper cup and pills.
June 5, 2024
Oral semaglutide proven effective in managing type 2 diabetes and enhancing cardiovascular health
Read More
Woman experiencing menopause.
February 3, 2026
Combination of Hormone Therapy and Tirzepatide Linked to Greater Weight Loss After Menopause, Study Finds
Read More

CCH LINKS

FAQ
HOW TO APPLY
ACADEMIC ADVISORY BOARD
FACULTY AND STAFF
TERMS & CONDITIONS
CCH EDUCATION SERVICES

OUR PARTNERS

NOF
Haringey Obesity Alliance
Skills Active
CPD UK
ASO
REPS
Southwark
DIT
Healthcare Uk
OAC

ABOUT CCH

CONTACT US
[email protected]
+44 (0)20 3773 4895
Technopark, 90 London Road, LONDON, SE1 6LN
 

© The College of Contemporary Health